Vimarsana
Biggest News Aggregation in the World

Page 19 - Thomas Biegi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomas Biegi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomas Biegi Today - Breaking & Trending Today

MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy - Vimarsana News

MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy

Press release content from Accesswire. The AP news staff was not involved in its creation.

Source: apnews.com
MorphoSys AG: MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease - Vimarsana News

MorphoSys AG: MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner Roche received Breakthrough Therapy Designation by the U.S. Food

Invitation to MorphoSys' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021 - Vimarsana News

Invitation to MorphoSys' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021

Invitation to MorphoSys' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021 ACCESSWIRE 22 Jul 2021, 06:31 GMT+10 PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT). MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and...

MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals - Vimarsana News

MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals

MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals ACCESSWIRE 17 Jun 2021, 08:31 GMT+10 PLANEGG, GERMANY / ACCESSWIRE / June 16, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) ('MorphoSys') today announced that it is commencing a cash tender offer to purchase all outstanding shares of Constellation Pharmaceuticals, Inc., (CNST) ('Constellation') for $34.00 per share, net to the seller in cash, without interest, and subject to any applicable withholding of taxes. The tender offer is being made pursuant to the previously announced merger agreement, date...

MorphoSys AG: MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL - Vimarsana News

MorphoSys AG: MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc.,